These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24845612)

  • 1. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
    Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
    J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
    Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
    Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
    Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
    J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
    Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
    Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
    Gnani D; Romito I; Artuso S; Chierici M; De Stefanis C; Panera N; Crudele A; Ceccarelli S; Carcarino E; D'Oria V; Porru M; Giorda E; Ferrari K; Miele L; Villa E; Balsano C; Pasini D; Furlanello C; Locatelli F; Nobili V; Rota R; Leonetti C; Alisi A
    Cell Death Differ; 2017 May; 24(5):889-902. PubMed ID: 28338656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone-modifying genes as biomarkers in hepatocellular carcinoma.
    Hung SY; Lin HH; Yeh KT; Chang JG
    Int J Clin Exp Pathol; 2014; 7(5):2496-507. PubMed ID: 24966962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutual regulation between CHD5 and EZH2 in hepatocellular carcinoma.
    Xie CR; Li Z; Sun HG; Wang FQ; Sun Y; Zhao WX; Zhang S; Zhao WX; Wang XM; Yin ZY
    Oncotarget; 2015 Dec; 6(38):40940-52. PubMed ID: 26517514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients.
    Feng H; Yu Z; Tian Y; Lee YY; Li MS; Go MY; Cheung YS; Lai PB; Chan AM; To KF; Chan HL; Sung JJ; Cheng AS
    J Hepatol; 2015 May; 62(5):1100-11. PubMed ID: 25500144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.
    Gherardi S; Ripoche D; Mikaelian I; Chanal M; Teinturier R; Goehrig D; Cordier-Bussat M; Zhang CX; Hennino A; Bertolino P
    Biochim Biophys Acta Gene Regul Mech; 2017 Apr; 1860(4):427-437. PubMed ID: 28215965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis.
    Chen S; Pu J; Bai J; Yin Y; Wu K; Wang J; Shuai X; Gao J; Tao K; Wang G; Li H
    J Exp Clin Cancer Res; 2018 Jan; 37(1):3. PubMed ID: 29316949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
    Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
    Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
    Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
    Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
    He C; Xu J; Zhang J; Xie D; Ye H; Xiao Z; Cai M; Xu K; Zeng Y; Li H; Wang J
    Hum Pathol; 2012 Sep; 43(9):1425-35. PubMed ID: 22406368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Chen S; Chen J; Zhan Q; Zhu Y; Chen H; Deng X; Hou Z; Shen B; Chen Y; Peng C
    Oncotarget; 2014 Nov; 5(21):10421-33. PubMed ID: 25431952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic alterations contribute to promoter activity of imprinting gene IGF2.
    Zheng QF; Xu B; Wang HM; Ding LH; Liu JY; Zhu LY; Qiu H; Zhang L; Ni GY; Ye J; Gao SB; Jin GH
    Biochim Biophys Acta Gene Regul Mech; 2018 Feb; 1861(2):117-124. PubMed ID: 29413895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
    Oh EJ; Yang WI; Cheong JW; Choi SE; Yoon SO
    Hum Pathol; 2014 Oct; 45(10):2043-50. PubMed ID: 25149548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.